SCHEMBL1421354

SCHEMBL1421354

COC(=O)c1ccc(N=C=S)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.56
MAPT P10636 6/20 0.56
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CA1 P00915 4/20 0.55
CA2 P00918 4/20 0.55
TDP1 Q9NUW8 1/20 0.52
CA12 O43570 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
NPC1 O15118 5/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
ACR P10323 3/20 0.51
HGFAC Q04756 1/20 0.51
PRSS1 P07477 1/20 0.50
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9953733 0.88 RAB9A (0.53) RAB9AMAPTCASP3SENP8SENP7
SCHEMBL9748412 0.85 HSD17B10 (0.46) RAB9AMAPTCASP3SENP8SENP7
SCHEMBL11646899 0.85 RAB9A (0.59) RAB9AMAPTCASP3SENP8SENP7
SCHEMBL445414 0.83 RAB9A (0.58) RAB9AMAPTCASP3SENP8SENP7
SCHEMBL1457515 0.81 MAPT (0.56) RAB9AMAPTCA1CA2TDP1
SCHEMBL2590530 0.81 CA1 (0.45) RAB9AMAPTCASP3SENP8SENP7
SCHEMBL29754225 0.80 ALDH1A1 (0.48) RAB9AMAPTCASP3SENP8SENP7
SCHEMBL1421363 0.80 ALDH1A1 (0.48) RAB9AMAPTCASP3SENP8SENP7
SCHEMBL9748423 0.79 MIF (0.53) RAB9AMAPTCASP3SENP8SENP7
SCHEMBL1308638 0.79 NOS3 (0.53) RAB9AMAPTL3MBTL1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104219954-B Benzamide derivatives 翻译基因组学研究院 2017-03-22 CN claimed
EP-2445345-B1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RES INST (US) 2014-08-27 EP claimed
US-10590088-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) 2020-03-17 US disclosed
US-10590088-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) 2020-03-17 US disclosed
US-20190084940-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2019-03-21 US disclosed
US-20190084940-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2019-03-21 US disclosed
CN-104219954-B Benzamide derivatives 翻译基因组学研究院 2017-03-22 CN disclosed
US-20160362382-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2016-12-15 US disclosed
US-9464059-B2 Benzamide derivatives THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-10-11 US disclosed
US-20150284336-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2015-10-08 US disclosed
US-9125901-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2015-09-08 US disclosed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO disclosed
WO-1999021845-A2 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES AGOURON PHARMACEUTICALS, INC. (US) 1999-05-06 WO disclosed
EP-0355819-B1 Substituted aryl ureas as high potency sweeteners NUTRASWEET CO (US) 1994-01-05 EP disclosed
EP-0299533-B1 HIGH POTENCY SWEETENING AGENTS THE NUTRASWEET COMPANY (a Delaware corporation) (US) 1993-04-07 EP disclosed
CN-1043125-A Be used as the aryl urea of the replacement of high-potency sweetener NUTRASWEET CO (US) 1990-06-20 CN disclosed
EP-0355819-A1 Substituted aryl ureas as high potency sweeteners THE NUTRASWEET COMPANY (a Delaware corporation) (US) 1990-02-28 EP disclosed
CN-1033624-A High-potency sweetener NUTRASWEET CO (US) 1989-07-05 CN disclosed
WO-1989000563-A1 HIGH POTENCY SWEETENING AGENTS THE NUTRASWEET COMPANY (US) 1989-01-26 WO disclosed
EP-0299533-A2 High potency sweetening agents THE NUTRASWEET COMPANY (a Delaware corporation) (US) 1989-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590088-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof MCL1, BRDT, BOD1L1 RAB9A 858/4885MAPT 4683/4885CASP3 342/4885
US-20150284336-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 RAB9A 1578/4885MAPT 4124/4885CASP3 184/4885
US-20160362382-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 RAB9A 1578/4885MAPT 4124/4885CASP3 184/4885
US-20190084940-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 RAB9A 1578/4885MAPT 4124/4885CASP3 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.